Business Wire

METANOMIC

18.5.2022 09:32:04 CEST | Business Wire | Press release

Share
Metanomic Acquires Intoolab, Developers of the First Bayesian Network Artificial Intelligence Engine

Today, Metanomic (https://www.metanomic.net/ ) announces it has acquired Intoolab A.I (https://www.intoolab.com/ ) , a Bayesian Network Artificial Intelligence company, to expand and to improve data analysis and A.I across video games and Web3. This acquisition augments Metanomic’s current game economy infrastructure that allows developers to build, simulate and run balanced game economies and core gameplay loops in a live, real-time environment.

The addition of artificial intelligence helps developers create better experiences through intelligent insight from player behaviour in run-time. As a part of the acquisition the existing solution will be rebranded to Thunderstruck and extend the capabilities of the Metanomic Engine.

A more intelligent approach to video game development and Web3 analytics

Thunderstruck is based on a new approach to artificial intelligence that is not based on off the shelf machine learning algorithms but a powerful combination of Deep Learning and Dynamic Bayesian Networks. The solution has already been successfully proven in Healthcare and the technology is now being applied initially to video games and Web3 in a number of core applications -

  • Web 3 Intelligence relating to game and NFT discovery and recommendation for tailored and personalized results to the user or player
  • Game Economy Intelligence providing Economy Balance Prediction, Gamer Categorisation, Gameplay Recommendations, Retention Strategies and NPC Intelligence
  • Ad Categorization delivers analytics around player and consumer classification both on and off-chain for in-game advertising networks to drive more personalized results
  • DeFI Intelligence providing on and off-chain user profiling for DeFi insight into asset purchases and income for new products and services, reputation scoring and more.

“Web3 and metaverse are the next big thing that will affect our everyday lives in so many dimensions and we couldn’t be at a better place and time with our technology, to take the next step and introduce Dynamic Bayesian Networks to this untapped and exciting new market,” said Nikos Tzagkarakis , CEO and Co-founder of IntooLab who joins Metanomic as their incoming Chief AI Officer.

“We knew from the first time we met Theo and the rest of the team, that joining the incredible Metanomic powerhouse is our best bet to be part of an unmatched platform for Web3, game economies and the metaverse.

“The incredible traction we’ve seen across both the traditional games industry, web3, and play-and-earn games for the beta of our economy platform already puts us in a strong position to help developers build more fun and engaging experiences,” Theo Priestley, CEO of Metanomic said.

"With the acquisition of an artificial intelligence platform we can deliver more power to developers through real-time player insight as well as the most advanced game economy solution in the industry.”

With the acquisition also comes the commitment to continue to build the company’s development hub in Greece, supporting the local startup community and tech economy.

Thunderstruck is available for trial and partner integration from today. The Metanomic Engine is a complete, free to use game economy design and run-time solution for game developers across Web3 and traditional games and is currently in a closed beta. To sign up for the waiting list email hello@metanomic.net

About Metanomic

Metanomic is the first and only complete real-time economy as a service platform for developers. Built by professional economists and game designers, the platform utilizes patented algorithms to easily deploy plug and play, interoperable and infinitely scalable game and creator economies ready for web3, metaverse, and play-and-earn games. The platform allows developers to easily and quickly build a fully-scalable and configurable play-and-earn economy that features asset creation engines and fully balanced player markets.

About Intoolab

Founded in 2017, Intoolab has always been technology-first, building the first production ready Dynamic Bayesian Networks intelligence that can be a milestone neurosymbolic step towards A.I. frameworks that understand the human concepts structurally and not just correlationally.

Tzager is the first Bayesian Inference A.I. framework, built for biomedical research, drug discovery, and personalized medicine with the main features being Pathway Simulations, Predictor Research/Models, and Literature Intelligence. Tzager is not just another deep learning algorithm trained to solve very specific problems, but an intelligent system with its own framework.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye